367 related articles for article (PubMed ID: 34711632)
61. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
[TBL] [Abstract][Full Text] [Related]
62. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review.
Shachar SS; Korzets Y; Shepshelovich D; Zlothover N; Amir E; Tibau A; Goldvaser H
Cancer Treat Rev; 2024 Jan; 122():102666. PubMed ID: 38064877
[TBL] [Abstract][Full Text] [Related]
63. Accelerated approval of oncology products: a decade of experience.
Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
[TBL] [Abstract][Full Text] [Related]
64. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study.
Etan T; Amir E; Tibau A; Yerushalmi R; Moore A; Shepshelovich D; Goldvaser H
Cancer Treat Rev; 2020 Dec; 91():102113. PubMed ID: 33128993
[TBL] [Abstract][Full Text] [Related]
65. FDA regulatory considerations for the review of drugs intended to treat pediatric cancers and rare tumors.
Bradford D; Singh H; Donoghue M
Curr Opin Pediatr; 2023 Feb; 35(1):48-54. PubMed ID: 36592026
[TBL] [Abstract][Full Text] [Related]
66. New drug approvals in oncology.
Kurzrock R; Kantarjian HM; Kesselheim AS; Sigal EV
Nat Rev Clin Oncol; 2020 Mar; 17(3):140-146. PubMed ID: 32020042
[TBL] [Abstract][Full Text] [Related]
67. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
Donoghue M; Lemery SJ; Yuan W; He K; Sridhara R; Shord S; Zhao H; Marathe A; Kotch L; Jee J; Wang Y; Zhou L; Adams WM; Jarral V; Pilaro A; Lostritto R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2012 Mar; 18(6):1496-505. PubMed ID: 22282463
[TBL] [Abstract][Full Text] [Related]
68. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
69. A note on breast cancer trials with pCR-based accelerated approval.
Xia Y; Cui L; Yang B
J Biopharm Stat; 2014; 24(5):1102-14. PubMed ID: 24926729
[TBL] [Abstract][Full Text] [Related]
70. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
71. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
Wagner J; Marquart J; Ruby J; Lammers A; Mailankody S; Kaestner V; Prasad V
BMJ; 2018 Mar; 360():k668. PubMed ID: 29514787
[TBL] [Abstract][Full Text] [Related]
72. Impact of an evolving regulatory landscape on skin cancer drug development in the U.S.
Miller DM; Shalhout SZ; Casey D; Fashoyin-Aje L; Lemery S; Theoret MR; Pazdur R
Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670678
[TBL] [Abstract][Full Text] [Related]
73. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
[TBL] [Abstract][Full Text] [Related]
74. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
[TBL] [Abstract][Full Text] [Related]
75. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
Pease AM; Krumholz HM; Downing NS; Aminawung JA; Shah ND; Ross JS
BMJ; 2017 May; 357():j1680. PubMed ID: 28468750
[No Abstract] [Full Text] [Related]
76. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications.
Cristina Mendonça Nogueira T; Vinicius Nora de Souza M
Bioorg Med Chem; 2021 Sep; 46():116340. PubMed ID: 34416511
[TBL] [Abstract][Full Text] [Related]
77. Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias.
Ribeiro TB; Colunga-Lozano LE; Araujo APV; Bennett CL; Hozo I; Djulbegovic B
J Clin Epidemiol; 2022 Aug; 148():193-195. PubMed ID: 35093531
[TBL] [Abstract][Full Text] [Related]
78. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.
Wilson BE; Desnoyers A; Nadler MB; Tibau A; Amir E
Cancer Med; 2021 Aug; 10(16):5405-5414. PubMed ID: 34323019
[TBL] [Abstract][Full Text] [Related]
79. Neoadjuvant therapy as a platform for drug development and approval in breast cancer.
Bardia A; Baselga J
Clin Cancer Res; 2013 Dec; 19(23):6360-70. PubMed ID: 24298066
[TBL] [Abstract][Full Text] [Related]
80. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
